PLX — Protalix Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $148.30m
- $114.90m
- $53.40m
- 55
- 56
- 39
- 49
Annual cashflow statement for Protalix Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.52 | -27.6 | -14.9 | 8.31 | 2.93 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 6.25 | 6.28 | 0.856 | 2.81 | 3.39 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -27.1 | 9.9 | -12 | -10.5 | 0.811 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -26.1 | -10.3 | -25 | -1.32 | 8.67 |
| Capital Expenditures | -0.655 | -1.46 | -0.628 | -1.15 | -1.28 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -19.3 | 20.4 | -4.41 | -15.6 | 5.5 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -20 | 18.9 | -5.04 | -16.7 | 4.22 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 46.5 | 12.1 | 8.24 | 24.7 | -16.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.473 | 20.7 | -21.9 | 6.52 | -3.87 |